Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesCorrelation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes
International Journal of Antimicrobial Agents, 06/15/09
Matsumoto K et al. - Non-linear pharmacokinetic analysis suggested that voriconazole therapy should be initiated with a dose of 7.2–8.9 mg/kg/day for CYP2C19 wild-type and 4.4–6.5 mg/kg/day for the non-wild-type in Japanese patients. These recommended initial dosages and subsequent dose adjustment for the target concentration range by therapeutic drug monitoring should avoid adverse events and thus enable continued effective voriconazole therapy for Japanese patients with mycoses.
Today in Antimicrobials...keeping you current
Receive free subspecialty "5-minute updates" via email
Comparison between concentrations of amphotericin B in infected lung lesion and in uninfected lung tissue in a patient treated with liposomal amphotericin B
International Journal of Infectious Diseases, 12/04/09
Oral ondansetron for reducing vomiting secondary to acute gastroenteritis in children – a double-blind randomized study
Alimentary Pharmacology and Therapeutics, 12/04/09
Early and Late Direct Costs in a Southern African Antiretroviral Treatment Programme: A Retrospective Cohort Analysis
PLoS Medicine, 12/04/09
Today in Dosing...keeping you current
Receive free subspecialty "5-minute updates" via email
High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial
BMC Infectious Diseases, 12/03/09
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: A double- blind, randomized, multicentre, placebo-controlled trial
Amyotrophic Lateral Sclerosis, 12/03/09
Ustekinumab (Stelara): First-in-class human monoclonal antibody approved for treatment of moderate-to-severe plaque psoriasis
Formulary , 12/02/09
Sponsor
Article Search
Sponsor